Saw this in cafe pharma.
SG Cowen September 6th. Galderma Looks Attractive; Annual Sales Around $2B; Leader in Dermatology. Of our screened targets, Galderma looks to be the most attractive. It is a globally diversified dermatology company jointly owned by Swiss-based L'Oreal and Nestle. While it is unclear to us whether the parent companies would even contemplate a sale, we have used it in our hypothetical scenario as an example of the type of attractive assets that could be available to Allergan. Galderma's presence in dermatology and aesthetics could deepen Allergan's capabilities in the space. According to the Galderma 2012 financial statements/annual report, it has 7% share of the worldwide dermatology market. Galderma reported roughly $2B (1.6B Euros) in sales in 2012, comprised of aesthetic (20%), OTC/self-medication (27%) and dermatology (53%). About 50% of sales is from North America, another 25% is from Europe and the rest in Latin America/ROW. This data suggests a clear geographic and therapeutic overlap in sales force capabilities between the two companies. In addition, in 2012, Galderma disclosed that it spent over 19% of sales in R&D. Given these statements, we believe that cost synergies could be attractive. The annual report notes that sales grew 13% in 2012 and 17% in 2011. Galderma could also provide a valuable pipeline in dermatology, with 12 new chemical entities in Phase II and III development.
you seem to be taking FDA Warning Letter lightly. Please google what they did to some pharma companies after FDA warning letter. Thank you
"So you can keep posting the Bad list and Joe can keep posting the Good list, SPPI will do what SPPI will do. Less"
Tartia, The big open question here is what will regulators do?
Management Integrity is What Buffet as the Important Quality when investing in stock
are you a nutcase ? A company with 1000 years of pharma sales experience did not know Fusilev was being stock by wholesalers or that Fusilev (with no label advantage over generic leucovorin) sales (at least the hospital side) will tank when leucovorin is in abundance.
GO TELL A KID . SEC WILL NOT LISTEN TO THIS BS
keep pumping. Can anybody trust the management here after so many of their statements have been proven wrong for years now....forget all those misleading statement...just take the fusilev fiasco where management went to every investor conf and kept pumping and stating "fusilev will not be impacted once generic leucovorin is back in supply" TIME AND TIME AGAIN when asked by analyst. How can management be so irresponsible and reckless towards investing public ?
How do you explain fda's love letter on Zevalin Marketing practices ?
And then tell me what did Buffet say ? "Management integrity is a must when investing in a stock/business"
Now tell me which one is true or false
i guess the wrinkle treatment has NOT done well in the market since its introduction 2 years. treatment is pretty cumbersome which is likely the reason why it will not do well.
could be a good use of taro's cash hoard. Fibrocell has a approved product to treat wrinkles as well technology that break into large markets related to medical aesthetic.
5 cents per post?
you are simply a dumb #$%$. Forward look statements should be based on REAL and REASONABLE information known not some out of the blue misleading number.
Are you saying a company with 1000 years of Pharma sales experience was NOT aware of
1. Hospital will buy generic leucovorin (NOT fusilev which is Many times expensive ) when generic shortage eases.
Despite knowing this, we kept hearing Fusilev sales will grow and Fusilev sales will NOT be impacted by generic leucovorin entry.
1. Zevalin will do $300m/year in a few years. This prediction has been going on since 2010 (correct me if I am wrong..)
2. Fusilev sales will grow from 2012 base. Fact: Fusilev sales decline 45% since 2012.
3. Fusilev sales will NOT be impacted by ease in shortage of generic leucovorin. Fact: Fusilev sales has decline 45% from ease in generic leucovorin.
4. Folotyn sales will double in a few years if we can have Fusilev treat mucositis in Folotyn patients and they will do a clinical trial on this.Fact: This is no longer being talked.
5. Apaz is being discussed as though FDA is close to approving a new Phase 3 trial and that the old phase 3 trial design was faulty. Fact: Nothing has happened on this since failure of Phase 3 trial in April 2012.
Could they pleasantly surprise ALL shareholders by announcing an earnings call and a webcast of it ?